171 related articles for article (PubMed ID: 16815667)
1. Anti-angiogenic and anti-HER therapy.
Gasparini G; Sarmiento R; Longo R
Biomed Pharmacother; 2006 Jul; 60(6):263-5. PubMed ID: 16815667
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapies in bladder cancer--an update.
Black PC; Agarwal PK; Dinney CP
Urol Oncol; 2007; 25(5):433-8. PubMed ID: 17826665
[TBL] [Abstract][Full Text] [Related]
3. [Angiogenesis inhibitor therapies: focus on hypertension and kidney toxicity].
Izzedine H
Bull Cancer; 2007 Nov; 94(11):981-6. PubMed ID: 18055316
[TBL] [Abstract][Full Text] [Related]
4. [Inhibition of angiogenesis by proteins, peptides and "small molecules"].
Jayson G; Armand JP; Berdel WE
Onkologie; 2005 Oct; 28 Suppl 4():29-34. PubMed ID: 16205103
[No Abstract] [Full Text] [Related]
5. [Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
Grimm CF; Blum HE; Geissler M
Dtsch Med Wochenschr; 2005 Jun; 130(23):1438-42. PubMed ID: 15929020
[No Abstract] [Full Text] [Related]
6. Current overview of angiogenesis inhibitors.
Ellis LM
Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
[No Abstract] [Full Text] [Related]
7. Anti-angiogenic therapy: concept to clinic.
Young RJ; Reed MW
Microcirculation; 2012 Feb; 19(2):115-25. PubMed ID: 22078005
[TBL] [Abstract][Full Text] [Related]
8. Tumoral angiogenesis: review of the literature.
Khosravi Shahi P; Fernández Pineda I
Cancer Invest; 2008 Feb; 26(1):104-8. PubMed ID: 18181052
[TBL] [Abstract][Full Text] [Related]
9. Tumor angiogenesis and anti-angiogenic therapies.
Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
[TBL] [Abstract][Full Text] [Related]
10. A targeted approach for antiangiogenic therapy of metastatic human colon cancer.
Ellis LM
Am Surg; 2003 Jan; 69(1):3-10. PubMed ID: 12575772
[TBL] [Abstract][Full Text] [Related]
11. In pursuit of new anti-angiogenic therapies for cancer treatment.
Cai J; Han S; Qing R; Liao D; Law B; Boulton ME
Front Biosci (Landmark Ed); 2011 Jan; 16(3):803-14. PubMed ID: 21196204
[TBL] [Abstract][Full Text] [Related]
12. [Anti-angiogenetic agents for solid tumors].
Blay JY
Rev Med Interne; 2007 Jun; 28 Suppl 1():S7-8. PubMed ID: 17482319
[No Abstract] [Full Text] [Related]
13. Angiogenesis as a strategic target for ovarian cancer therapy.
Spannuth WA; Sood AK; Coleman RL
Nat Clin Pract Oncol; 2008 Apr; 5(4):194-204. PubMed ID: 18268546
[TBL] [Abstract][Full Text] [Related]
14. [Molecular targets in colon cancer].
Borner MM
Ther Umsch; 2006 Apr; 63(4):243-8. PubMed ID: 16689454
[TBL] [Abstract][Full Text] [Related]
15. Breast tumour angiogenesis.
Fox SB; Generali DG; Harris AL
Breast Cancer Res; 2007; 9(6):216. PubMed ID: 18190723
[TBL] [Abstract][Full Text] [Related]
16. Is VEGF a predictive biomarker to anti-angiogenic therapy?
Otrock ZK; Hatoum HA; Musallam KM; Awada AH; Shamseddine AI
Crit Rev Oncol Hematol; 2011 Aug; 79(2):103-11. PubMed ID: 20724177
[TBL] [Abstract][Full Text] [Related]
17. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
18. Vascular normalization: study examines how antiangiogenesis therapies work.
Webb T
J Natl Cancer Inst; 2005 Mar; 97(5):336-7. PubMed ID: 15741568
[No Abstract] [Full Text] [Related]
19. [Antiangionic drugs in soft tissue sarcoma].
Salas S; Huynh T; Deville JL; Duffaud F
Bull Cancer; 2010 Jun; 97(6):701-5. PubMed ID: 20483703
[TBL] [Abstract][Full Text] [Related]
20. [Inhibition of the VEGF receptor system with tyrosine kinase inhibitors. Angiogenesis inhibition in oncology].
Mross K
Pharm Unserer Zeit; 2008; 37(5):404-15. PubMed ID: 18729270
[No Abstract] [Full Text] [Related]
[Next] [New Search]